Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AbbVie Raises Guidance Based On Humira Patent Umbrella

This article was originally published in Scrip

Executive Summary

Analyst buzz about the AbbVie Inc. third quarter earnings call Oct. 30 centered on its strongly optimistic sales guidance through 2020, based on its belief in a suite of intellectual property that it says will protect top-seller Humira from US biosimilar competition until 2022 or later.



Related Companies